Comparative Pharmacology
Head-to-head clinical analysis: E E S 400 versus ERYTHROMYCIN LACTOBIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 400 versus ERYTHROMYCIN LACTOBIONATE.
E.E.S. 400 vs ERYTHROMYCIN LACTOBIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
Erythromycin lactobionate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the translocation of peptides. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
1-4 g/day IV divided every 6 hours; maximum 4 g/day. Infuse over 20-60 minutes.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Terminal elimination half-life: 1.4-2.0 hours in adults with normal renal function. In patients with anuria, half-life may be prolonged up to 4.8-6.0 hours.
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Primarily biliary excretion (80-90% as unchanged drug and metabolites); renal excretion accounts for 10-15% of the dose. Fecal elimination is minimal (<5%).
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic